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Healthcare workers (HCW) were prioritized for vaccination during the 2009 inﬂuenza A(H1N1)pdm09 pandemic. We
conducted a clinical trial in October 2009 where 237 HCWs were immunized with a AS03-adjuvanted A(H1N1)pdm09
monovalent vaccine. In the current study, we analyzed the homologous and cross-reactive H1N1 humoral responses
using prototype vaccine strains dating back to 1977 by the haemagglutinin inhibition (HI), single radial hemolysis SRH),
antibody secreting cell (ASC) and memory B cell (MBC) assays. The cellular responses were assessed by interferon-g
(IFN-g) ELISPOT and by intracellular staining (ICS) for the Th1 cytokines IFN-g, interleukin-2 (IL-2) and tumor necrosis
factor-a (TNF-a). All assays were performed using blood samples obtained prior to (day 0) and 7, 14 and 21 d post-
pandemic vaccination, except for ASC (day 7) and ICS (days 0 and 21). Vaccination elicited rapid HI, SRH and ASC
responses against A(H1N1)pdm09 which cross reacted with seasonal H1N1 strains. MBC responses were detected against
the homologous and seasonal H1N1 strains before vaccination and were boosted 2 weeks post-vaccination. An increase
in cellular responses as determined by IFN-g ELISPOT and ICS were observed 1–3 weeks after vaccination. Collectively,
our data show that the AS03-adjuvanted A(H1N1)pdm09 vaccine induced rapid cellular and humoral responses against
the vaccine strain and the response cross-reacted against prototype H1N1 strains dating back to 1977.
Introduction
The novel, swine-origin influenza A(H1N1)pdm09 virus was
first detected in April 2009 and it caused the first influenza pan-
demic of the 21st century. The A(H1N1)pdm09 virus was anti-
genically distinct from the prior seasonal influenza A strains and
the majority of the population was immunologically na€ıve to A
(H1N1)pdm09 rendering existing influenza vaccines ineffective
against this strain.1-3 New pandemic vaccines were developed
against A(H1N1)pdm09 and they induced sero-protective anti-
body responses 1-2 weeks after administering a single dose in
most healthy adults.4 Since 2009, the A(H1N1)pdm09 virus has
circulated and has been included in the seasonal trivalent influ-
enza vaccines (TIV) as the H1N1 strain.
Antibody responses are a key mediator of sero-protective
immunity induced by influenza vaccines.5 At the start of the
pandemic, there were no or little antibody titres against the A
(H1N1)pdm09 strain, especially in young adults and children
resulting in atypically high rates of severe disease.2,3 However,
people over the age of 60 had higher levels of sero-protective
immunity, most likely due to having pre-existing, cross-reactive
antibodies from prior exposure to A(H1N1)pdm09-like strains
in the distant past.6 In this regard, infection with A(H1N1)
pdm09 has been shown to activate broadly-cross reactive memory
B cells that provided protection even in the absence of pre-exist-
ing antibody titres.7 Of interest, recent studies have shown that
antibodies specific for the conserved stalk domain of the influenza
haemagglutinin were boosted by vaccination and infection with
the novel A(H1N1)pdm09 virus and these antibodies have broad
cross-reactive neutralizing activity against different group 1 influ-
enza strains.6,8,9 In addition to antibody responses, T cells play a
significant role in anti-influenza immunity. A large percentage of
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T-cell epitopes found in seasonal H1N1 strains in the years pre-
ceding the pandemic were conserved in A(H1N1)pdm09, thus
were targets of immunological memory.10 A recent report
showed that high frequencies of pre-existing T cells to conserved
epitopes on A(H1N1)pdm09 virus were found in people that
developed less severe disease, suggesting a key role for cellular
immunity in anti-A(H1N1)pdm09 responses.11
During the 2009 pandemic, HCWs were prioritized for vacci-
nation in order to maintain the integrity of the healthcare system
and to minimize virus transfer to vulnerable patients. In October
2009, we conducted a clinical trial in frontline HCWs to evaluate
the safety and immunogenicity of a single dose of a A(H1N1)
pdm09 vaccine formulated with the oil-in-water adjuvant AS03.
Vaccination commenced 2–3 weeks prior to the peak of pan-
demic activity. The vaccine was well tolerated and by using the
HI assay, we showed that sero-protective responses (titres 40)
were elicited in a majority of subjects (97%) by 2–3 weeks after
vaccination.4 Further studies have shown that influenza vaccines
formulated with the oil-in-water adjuvant AS03 to be safe and
highly efficacious in children, young adults and the elderly.4,12-20
In the current study, we characterized in detail the homolo-
gous and cross-reactive humoral and cellular response in HCW
after AS03-adjuvanted A(H1N1)pdm09 vaccination. Our results
show that vaccination induced serological (HI and SRH) and B
cell (ASC and MBC) responses against A(H1N1)pdm09 and
protoype seasonal H1N1 vaccine viruses that prevailed in the
years preceding the pandemic. Furthermore, by IFN-g ELISPOT
and intracellular cytokine staining assays, we demonstrate that
both homologous and cross-reactive Th1 cytokine responses are
elicited in HCWs after vaccination with the AS03-adjuvanted A
(H1N1)pdm09 vaccine.
Results
In this study we have evaluated the early homologous and
cross reactive immune responses to prototype H1N1 vaccine
strains dating back to 1977 after a single low dose of pandemic
influenza vaccine adjuvanted with the oil-in-water adjuvant AS03
in frontline HCWs. Blood samples were taken at 4 consecutive
time points (day 0, 3, 7 and 14 post-vaccination) to evaluate the
dynamics of the homologous and cross-reactive immune response
to vaccination (Fig. 1).
The cross-reactive haemagglutinin inhibition (HI) antibody
response after pandemic vaccination
Figure 2 shows the post-vaccination HI response against the
homologous A/(H1N1)pdm09-like strain A/California/07/09
(California) and cross-reactivity against 6 seasonal influenza A
H1N1 viruses. A sero-protective HI response was defined as an
HI titer  40.21 Prior to vaccination, 13.5% of the subjects had
sero-protective HI titres against the homologous California strain
with a geometric mean titer (GMT) of 8. Vaccination boosted
the California-specific HI response where by day 7, a majority of
subjects (78%, GMT D 156) were seroprotected. The HI
response continued to increase up to days 14 and 21 post-
vaccination with 100% (GMT D 826) and 96% (GMT D 619)
of the subjects, respectively having sero-protective HI titres 40.
The HI assay was used to examine the cross-reactive HI
responses against 6 prototype H1N1 vaccine strains; A/USSR/
90/77 (USSR), A/Brazil/11/1978 (Brazil), A/Taiwan/1/86 (Tai-
wan), A/Texas/36/91 (Texas), A/New Caledonia/20/99 (New
Caledonia) and A/Brisbane/59/07 (Brisbane). Prior to vaccina-
tion, sero-protective HI titres were observed in HCWs against all
strains; USSR (26%, GMT D 13), Brazil (26%, GMT D 12),
Taiwan (39%, GMT D 24), Texas (56%, GMT D 60), New
Caledonia (31%, GMT D 15) and Brisbane (29%, GMT D 14)
strains. The post-vaccination HI response peaked on day 14 with
68–94% of subjects having sero-protective titres against USSR
(GMT D 116), Brazil (GMT D 145), Taiwan (GMT D 201),
Texas (GMT D 796), New Caledonia (GMT D 79), and Bris-
bane (GMT D 102) strains. Similar HI titres were observed on
day 21 post-vaccination with 59–90% subjects having sero-pro-
tective titres against USSR (GMT D 84), Brazil (GMT D 110),
Taiwan (GMT D 145), Texas (GMT D 653), New Caledonia
(GMT D 51) and Brisbane (GMT D 48) strains.
The cross-reactive single radial hemolysis (SRH) response
to vaccination
Figure 3 shows the pre- and post-vaccination SRH titres
against the homologous California and cross-reactive responses
against the New Caledonia and Texas strains. The European
Agency for Evaluation of Medicinal Products criterion of protec-
tive serological response to influenza vaccines is a SRH titer of
25 mm2, which was used as a cut-off for serologic protection.
Prior to vaccination, only 4% of the subjects had sero-protective
SRH titer of 25 mm2 against the Texas strain (GMT D 8),
while 24% and 51% of subjects had sero-protective titres against
California (GMT D 11) and New Caledonia (GMT D 16)
strains, respectively. One week after vaccination, a majority of
the subjects (76–84%) had sero-protective SRH titres against
New Caledonia (GMT D 35) and California (GMT D 41)
strains, while 28% had sero-protective SRH responses against the
Texas strain (GMT D 15). The SRH response peaked 2 weeks
after vaccination with 92–100% of the vaccinees having sero-pro-
tective responses against New Caledonia (GMT D 56) and Cali-
fornia (GMT D 73) strains. Lower SRH responses were detected
against the Texas strain with only 59% of subjects having
sero-protective titres at 2 weeks post vaccination (GMT D 25).
B cellular responses after pandemic vaccination
in health care workers
Antibody secreting cell response after vaccination
The humoral response was further characterized by ASC
response in peripheral blood mononuclear cells (PBMC) after
vaccination. The peak virus-specific ASC response were observed
at day 7 post-vaccination (Fig. 4), while no ASC responses were
observed before vaccination or at days 14 and 21 after vaccina-
tion (data not shown). IgG ASCs dominated the anti-California
response (mean D 111 ASC per 1 £ 105 PBMC) and was
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significantly higher than the IgA (P < 0.001) and the IgM
(P < 0.0001) ASC responses against the same strain (mean D 45
and 27 ASC per 1 £ 105 PBMC, respectively). Similarly, signifi-
cantly higher (P < 0.0001) IgG ASCs were detected against
Texas and New Caledonia strains (mean D 110 and 86 ASC per
1 £ 105 PBMC, respectively) compared with corresponding IgM
responses against the same strains (mean D 28 and 23 ASC per 1
£ 105 PBMC, respectively). In general, weak IgM ASC responses
were detected against all 3 H1N1 strains, which may suggest that
relatively low ASC responses were elicited against novel epitopes.
The memory B cell response after vaccination
Memory B cells (MBC) play a key role in anti-influenza
immunity. Figure 5 shows that, prior to vaccination, IgG
MBCs were detected against all the influenza A viruses tested
with mean frequencies ranging between 114–263 cells per 1 £
106 PBMC and no increase in the response was detected at
7 days after vaccination. The virus-specific IgG MBC frequen-
cies peaked at 14 days after vaccination with the highest
responses detected against the Brisbane and California strains
(mean 470 and 410 cells per 1 £ 106 PBMC, respectively) and
the lowest against the Brazil strain (mean 197 cells per 1 £ 106
PBMC). A significant increase (P < 0.05) in California-specific
IgG MBC frequency was observed at day 14 (mean 410 cells
per 1 £ 106 PBMC) compared to pre-vaccination (mean 200
cells per 1 £ 106 PBMC), while the responses against the other
strains were not significantly different. Furthermore, we found a
significant correlation between pre-vaccination MBC responses
against California and the 6 seasonal H1N1 influenza strains
with Spearman correlation coefficients (r) ranging between 0.6
and 0.96 (Table 1). A significant correlation was also observed
between pre-vaccination MBC frequencies and day 7 HI
responses against all viruses except the USSR and Brisbane
strains (Table 1).
Interferon gamma response after vaccination
Figure 6 shows the frequencies of PBMCs secreting IFN-g in
an antigen-specific manner prior to vaccination (day 0) and at 7,
14 and 21 days post-vaccination.
Before vaccination, the highest response was observed against
the Texas strain (mean number of IFN-gC cells per 1 £ 106
PBMC (mean) D 273) followed by the New Caledonia (mean D
100) and the Brisbane (mean D 51) strains, while the weakest
pre-vaccination IFN-g response was detected against the Califor-
nia strain (mean D 18). At 7 days post-vaccination, an increase in
IFN-g response was detected against the Brisbane (mean D 89),
New Caledonia (mean D 170) and Texas (mean D 273) strains,
although this was not significantly higher than pre vaccination
numbers. No significant increases in the IFN-g response were
observed on days 14 and 21 against any strain. Overall, the weak-
est IFN- g response was detected against the California strain,
however the response at 21 days post-vaccination (mean D 36)
was double that observed before vaccination (mean D 18).
Intracellular Th1 cytokine responses after vaccination
Figure 7 shows frequencies of CD4C T-cells producing either
single (A) or multiple (B) Th1 cytokines against California, New
Caledonia and Texas strains before and 21 days after vaccination.
Figure 1. The experimental plan. Two hundred and thirty seven healthcare workers were vaccinated with the 2009 A(H1N1)pdm09 monovalent split
virus vaccine (3.75 mg HA) formulated with the oil-in-water adjuvant AS03. The ﬁgure shows the number of samples (n) analyzed at each sampling day
(Day) for each immunological assay and the H1N1 strains against which the assays were performed. Consecutive blood samples were taken from the
same subject at 4 time points (day 0 7, 14 and 21 post-vaccination) for HI, SRH, ASC, memory B cell and IFN-g ELISPOT assays. For ICS, PBMCs were
obtained from 8 subjects before vaccination and a separate cohort of 18 subjects on day 21 post-vaccination. The ASC (n D 39) and ICS (nD 8–18) assays
were run on fresh PBMCs, whereas memory B cell (n D 16–27), and IFN-g ELISPOT (n D 9) assays were run on freeze/thawed PBMCs. * Strains used in the
SRH assay.
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Before vaccination (day 0), significantly lower (P < 0.05) IFN-g
responses were detected against California compared with the
New Caledonia and Brisbane strains. At 21 days post-vaccina-
tion, significantly higher (P < 0.05) IFN-g levels were detected
against all strains compared with pre-vaccination levels. Before
vaccination, significantly lower (P < 0.05) frequencies of IL-2
and TNF-a were observed against Brisbane compared with the
New Caledonia strain. Vaccination induced a significant increase
(P < 0.05) in IL-2 response against all 3 strains compared with
pre-vaccination levels. Increased TNF-a responses were also
detected after vaccination with significantly higher (P < 0.05)
frequencies detected against New Caledonia and Brisbane strains
on day 21 compared with day 0. Figure 7B shows the frequency
of Th1 cells simultaneously producing one or more cytokine
(multi-functional T cells). After vaccination (day 21), significant
increases (P < 0.05) in both triple and double cytokine produc-
ing cells were detected against all 3 strains compared with
pre-vaccinaion levels (Fig. 7B).
Discussion
The 1918 Influenza H1N1 pandemic killed up to 50 million
people and H1N1 strains continued to circulate in the human
Figure 3. Homologous and cross-reactive single radial hemolysis (SRH)
antibody responses after pandemic vaccination. The SRH response
against the homologous vaccine strain A/California/7/09 and 2 seasonal
inﬂuenza strains A/Texas/36/91 and A/New Caledonia/20/99 was deter-
mined before vaccination (day 0) and at 7, 14 and 21 days after vaccina-
tion. Each symbol represents the SRH titer of one subject, with
geometric means and 95% conﬁdence levels indicated. The dotted hori-
zontal line shows the sero-protective SRH titer of 25 mm2.
Figure 2. Homologous and cross-reactive haemagglutinin inhibition
response after pandemic vaccination. The HI response against the
homologous vaccine virus A/California/07/09 and 6 seasonal inﬂuenza
H1N1 strains A/USSR/90/77, A/Brazil/11/1978, A/Taiwan/1/86, A/Texas/
36/91, A/New Caledonia/20/99 and A/Brisbane/59/07 was determined
before vaccination (day 0) and at 7, 14 and 21 days after vaccination.
The bars show the geometric mean titer with 95% conﬁdence interval
and individual responses are presented as symbols. The dotted horizon-
tal line represents a sero-protective HI titer of 40.
Figure 4. The antibody secreting cell response 7 days after pandemic
vaccination. The A/Texas/36/91, A/New Caledonia/20/99 and A/Cali-
fornia/07/09-speciﬁc IgG, IgA and IgM ASC responses were measured
by ELISPOT 7 days after vaccination with AS03-adjuvaned pandemic
H1N1 vaccine. The bars represent mean numbers of virus-speciﬁc
ASCs per 100 000 peripheral blood mononuclear cells (PBMC) §
standard error of the mean. Statistical differences are shown by
non-parametric Kruskal-Wallis test. ** D P < 0.01, *** D P < 0.001,
**** D P < 0.0001.
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populations until 1957. From 1957 to 1977, H1N1 viruses
were not detected in human populations, most likely due to
competition from the H2N2 and H3N2 strains. However in
1977, influenza H1N1 re-emerged and circulated as a seasonal
virus until the 2009 pandemic.
Phylogenetic analysis of the H1N1 HA gene shows that the A
(H1N1)pdm09 strain is highly divergent from the seasonal
H1N1 strains, while the seasonal H1N1 strains from 1977 to
2008 are more closely related (Fig. S1). Despite the antigenic
divergence, infection with the A(H1N1)pdm09 virus induced
broad-cross reactive antibody responses against epitopes that are
conserved on the HA of seasonal H1N1 and A(H1N1)pdm09
strains.7,10 Antibody responses directed at common HA epitopes
may explain the broad cross-reactivity observed in our cohort fol-
lowing vaccination with the AS03-adjuvanted vaccine. The AS03
adjuvant itself may have contributed to the breath of the cross-
reactive response, however the underlying immunological mecha-
nisms for this are not clear. A control group that received a non-
adjuvanted A(H1N1)pdm09 vaccine would have shown the ben-
efits of the AS03 adjuvant, however this was not possible as only
the AS03 adjuvanted pandemic vaccine was licensed for use in
Norway in 2009. We found that 13% of HCW had preexisting
HI titres 40 to the California strain at baseline, which suggest
exposure or subclinical infection with this virus. Almost all
HCWs (97%) with preexisting sero-protective HI titres to A
(H1N1)pdm09 were under the age of 60, therefore were not
exposed to 1918-like H1N1 strains that have been shown to
induced cross-reactive antibodies against the A(H1N1)pdm09
virus.2 However, most of our study cohort (60%) had received
the trivalent seasonal influenza vaccines in years preceding the
2009 pandemic4 and this may have contributed to the preexisting
immunity against both the A(H1N1)pdm09 virus and the sea-
sonal H1N1 strains.2
When stratified by age, older subjects (persons born before
1957) had similar HI and SRH GMTs against A(H1N1)pdm09
and seasonal H1N1 strains at baseline compared with the youn-
ger cohort (Fig. S2). This differs from prior reports where higher
frequencies of sero-protective antibodies and significantly lower
infection rates have been observed in older adults over the age of
60 years.2 Compared with the general public, the potential for
exposure or asymptomatic subclinical infection is higher in
HCWs and this may explain relatively high baseline sero-protec-
tive rates we observed in younger HCWs.
In this study, we evaluated the serological responses by 2 com-
monly used assays; HI and SRH with contrasting results. While
both assays showed that vaccination induced complete protection
Figure 5. Homologous and cross-reactive memory B cells responses after
pandemic vaccination. The pre- and post-vaccination IgG memory B cell
responses were determined against the homologous vaccine strain A/
California/07/09 and cross-reactive responses against 6 seasonal inﬂu-
enza strains A/USSR/90/77, A/Brazil/11/1978, A/Taiwan/1/86, A/Texas/36/
91, A/New Caledonia/20/99 and A/Brisbane/59/07. The vertical bars rep-
resent the mean § standard error of the mean and each symbol repre-
sents one subject.
Table 1. Correlation between memory B cell responses to vaccine virus and seasonal H1N1 virus pre- and post-vaccination
Strain
Correlation prior to vaccination* Correlation post vaccination**
r P r P
USSR 0.95 0.0004 0.21 ns
Brisbane 0.96 0.0002 0.22 ns
Taiwan 0.82 0.0085 0.63 0.0006
Texas 0.6 0.0963 0.58 0.0023
NC 0.73 0.0304 0.43 0.0325
Brazil 0.95 0.0004 0.45 0.0207
California NA NA 0.81 0.0001
*Spearman correlation coefﬁcients (r) between memory B cell responses against the homologous vaccine virus A/California/07/09 and seasonal inﬂuenza
strains A/USSR/90/77, A/Brazil/11/1978, A/Taiwan/1/86, A/Texas/36/91, A/New Caledonia/20/99 (NC) and A/Brisbane/59/07 prior to vaccination.
**Spearman correlation coefﬁcients between memory B cell response prior to vaccination and haemagglutination inhibition titres at day 7 post-vaccination
against A/California/07/09, A/USSR/90/77, A/Brazil/11/1978, A/Taiwan/1/86, A/Texas/36/91, A/New Caledonia/20/99 and A/Brisbane/59/07 strains. ns D not
signiﬁcant. NAD not applicable.
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against A(H1N1)pdm09 by day 14, contrasting results were
observed against the Texas strain, with 100% and 59% seropro-
tection by HI and SRH assays, respectively. Generally there is a
good correlation between HI and SRH responses against influ-
enza A viruses22, therefore the discrepancy observed in our study
is intriguing. Perhaps this may reflect different sensitivities of
serological assays and measurement of different functionalities in
the antibodies against different influenza strains, however further
work is required to fully understand the measured differences.
The humoral immune response was further characterized by
evaluating the influenza-specific ASC andMBC responses. The day
7 post-vaccination ASC response corresponds to the peak plasma-
blast CD19CCD20¡CD27highCD38high response 23, and in our
study, we observed a significant increase in IgG and IgA ASCs
against the pandemic and seasonal H1N1 strains. The rapid ASC
response one week after vaccination has been shown to be consistent
with a recall response originating from activation of cross-reactive
MBCs generated by previous influenza infections and/or
vaccination.6,7,24 An important finding in our study is that memory
MBCs against A(H1N1)pdm09 strain were detected even before
vaccination or widespread circulation of the pandemic virus, at fre-
quencies similar to those observed against recently circulated sea-
sonal H1N1 strains, suggesting cross reaction to conserved
epitopes. Furthermore, we observed a significant positive correla-
tion between the pre-vaccination MBC response against A(H1N1)
pdm09 and that against the seasonalH1N1 strains (Table 1). A sig-
nificant positive correlation was also observed between the pre-vac-
cination MBC responses and day 7 HI titres against most of the
H1N1 strains tested. Collectively, our results strongly imply and
support the suggestion that MBCs targeting A(H1N1)pdm09 exist
in the human population and that they arise from prior exposure to
seasonal H1N1 strains.6 These A(H1N1)pdm09-specific MBCs
have the capacity to rapidly differentiate into ASCs that secrete IgG
antibodies after antigen re-encounter and have broad cross-reactiv-
ity.25-27 The pre-existing MBCs targeting the A(H1N1)pdm09
virus may at least partly explain the fact that rapid sero-protective
responses were elicited in a majority of subjects after only a single
dose of the pandemic vaccine.4 Further studies using chimeric virus
constructs could evaluate the specificity of the post-vaccination anti-
body and MBC responses toward the globular head and the rela-
tively well-conserved stalk domains of group 1 HA to confirm that
the cross reactivity observed is due to conserved epitopes on the H1
haemagglutinin.28 In this regard, immunization with chimeric virus
constructs derived from novel influenza strains was shown to induce
broadly cross-reactive HA stalk-specific antibody responses by
ELISA andmicroneutralization assays.29,30
Cellular responses play a significant role in anti-influenza immu-
nity (for a review see ref.31). To assess the vaccine induced T-cell
activity, we determined the influenza-specific IFN-g response by
ELISPOT and IFN-g, IL-2 and TNF-a responses by ICS. Both
ICS and ELISPOT analysis showed an increase in Th1 cytokine
(IFN-g, IL-2 and TNF-a) responses against both the A(H1N1)
pdm09 and seasonal H1N1 strains after vaccination. Both IFN-g
and TNF-a have powerful anti-influenza virus activity and increased
levels may help prevent severe influenza illness.32-34 Furthermore, we
observed an increase in homologous and cross-reactive Th1 CD4 T
cells simultaneously secreting more than one cytokine (multifunc-
tional T-cells), which are functionally superior to single cytokine
producing cells eliciting anti-influenza immunity and conferring
protection against lethal influenza infection.35,36 Furthermore, there
was an increase in IFN-gC IL-2C TNF-aC cells post-vaccination,
which have a high proliferative potential and are an important target
population for anti-A(H1N1)pdm-09 virus activity.37 Interestingly,
a very low A(H1N1)pdm09-specific IFN-g response was observed
prior to vaccination by both the ELISPOT and ICS assays compared
with responses against the seasonal strains. The higher baseline IFN-
gC cell frequencies observed against seasonal H1N1 viruses most
likely reflects a recall memory T cell response to prior influenza vac-
cine and/or infection. In our study, the pandemic split virus antigen
used for in vitro stimulation consists mainly of A(H1N1)pdm09
HA and NA, which shares only a few T-cell epitopes (12%) with
HA and NA of seasonal H1N1 strains 10, hence the pre-vaccination
response against A(H1N1)pdm09 would mainly be na€ıve T cells
directed toward novel epitopes. Na€ıve T cells require sustained
Figure 6. IFN-g responses against inﬂuenza A virus strains after pan-
demic vaccination. Peripheral blood mononuclear cells (PBMC) obtained
from individuals vaccinated with AS03-adjuvanted pandemic H1N1 vac-
cine were stimulated overnight with split virus antigens from the homol-
ogous vaccine virus A/California/7/09 and seasonal H1N1 strains A/
Texas/36/91, A/New Caledonia/20/99 and A/Brisbane/59/07 and the IFN-
g response was evaluated by the ELISPOT assay. Each symbol represents
one subject and with mean and standard error of the mean indicated.
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antigen stimulation over days to produce IFN-g in vitro 38, and this
may explain the lack of a pre-vaccination IFN-g response after over-
night stimulation in our ELISPOT and ICS assays.
In conclusion, we have shown that the AS03-adjuvanted A
(H1N1)pdm09 vaccine induces both humoral and cellular cross-
reactive immune responses in HCW and this may have played a
key role in eliciting rapid sero-protective immune responses, which
contributed significantly to maintaining the integrity of the health-
care system during the pandemic.4 Our results show that immune
responses originally primed by exposure to seasonal strains can be
recalled after pandemic vaccination and better understanding of
mechanisms that result in cross-reactive immune responses may
lead to the development of improved influenza vaccines.
Materials and Methods
Participants and study design
In October 2009, 237 frontline healthcare workers at the
Haukeland University Hospital, (Bergen, Norway) were
vaccinated with a single dose of the AS03 adjuvanted monovalent
split virus vaccine (Pandemrix, GlaxoSmithKline, www.clinical-
trials.gov, NCT01003288).4 All participants provided written
informed consent before being included in the study, which was
approved by the Regional Ethical committee of Western Norway
and the Norwegian Medicines Agency. The inclusion/exclusion
criteria for this study are published elsewhere.4 Consecutive
blood samples were taken from the same subject at 4 time points
(days 0, 7, 14 and 21 post-vaccination) for the serological (HI,
SRH), ASC, memory B cell and IFN-g ELISPOT assays. For the
intracellular cytokine staining (ICS) for Th1 cytokines, PBMCs
were obtained from 8 subjects before vaccination and a separate
cohort of 18 subjects on day 21 post-vaccination. On days 7 and
14, serological responses were determined in only 50 subjects as a
part of a kinetic sub-study (Fig. 1). Serum samples were ali-
quoted and stored at ¡70C before use in the serological assays.
PBMCs were isolated from a small group of HCWs (n D 39)
using Cell preparation Tubes (CPT, BD Biosciences) according
to manufacturer’s instructions. Fresh lymphocytes were used in
the antibody secreting cell ELISPOT assay and for intracellular
Figure 7. The single (A) and multi-functional (B) CD4C T-cell cytokine response before and 21 days after pandemic vaccination. Peripheral blood mono-
nuclear cells (PBMC) were obtained from 8 subjects before vaccination (day 0) and from a separate cohort of 18 subjects on day 21 post-A(H1N1)pdm09
vaccination. PBMCs were stimulated overnight with split virus antigens from A/New Caledonia/20/99, A/Brisbane/59/07 and A/California/07/09 viruses
and stained for intracellular cytokines (IFN-g, IL-2 and TNF-a) and the percentage of single cytokine producing (A) or muli-functioal (B) CD4 T-cells was
measured by ﬂow cytometry.Cgroup (day 21) signiﬁcantly different by Student t test from day 0 (P< 0.05).
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cytokine staining of CD4C T-cells. Remaining lymphocytes were
frozen at ¡70C and prioritized for use in the memory B cell
ELISPOT followed by the IFN-g ELISPOT assays.
Antibody assays
The haemagglutinin inhibition (HI) antibody response was
analyzed against the homologous A/(H1N1)pdm09-like strain
(A/California/07/09) and against 6 seasonal influenza A (H1N1)
strains (A/USSR/90/77, A/Brazil/11/1978, A/Taiwan/1/86, A/
Texas/36/91, A/New Caledonia/20/99 and A/Brisbane/59/07)
(Fig. S1). Assays were performed in duplicate and the geometric
mean titer (GMT) was calculated. The pre- and post-vaccination,
influenza-specific HI antibody response was determined by the HI
assay using 8 HA units of each virus strain and 0.7% turkey red
blood cells, as described earlier.4 HI titers were defined as the
reciprocal of the dilution exceeding 50% haemagglutination. Neg-
ative titers were assigned a value of 5 for calculation purposes.
The single radial hemolysis (SRH) responses against A/Texas/
36/91, A/New Caledonia/20/99 and A/California/07/09 strains
were conducted at the University of Siena, Italy, as previously
described.39-41
B cell assays
The virus-specific IgG, IgA and IgM antibody secreting cell
(ASC) response against A/California/07/09, A/Texas/36/91 and
A/New Caledonia/20/99 split virus antigens was determined pre
and post-vaccination by ELISPOT assay using fresh PBMCs as
described earlier.23 The numbers of IgG, IgA and IgM ASCs
were evaluated at 7 days post-vaccination, as this has previously
been shown to be the peak response after inactivated influenza
vaccination.23
The virus-specific IgG memory B cell (MBC) response against
A/California/07/09, A/Brisbane/59/07, A/Texas/36/91 and A/
New Caledonia/20/99 split virus antigens and A/USSR/90/77,
A/Brazil/11/1978, A/Taiwan/1/86 whole virus was quantified by
ELISPOT as described earlier.42 Results are presented as virus-
specific IgG MBC cells per 1 £ 106 PBMCs.
Interferon gamma ELISPOT assay
The influenza-specific IFN-g response pre and post-vaccina-
tion was examined by using 96 well plates pre-coated with anti-
IFN-g antibodies according to the manufacturers instructions
(Mabtech AB, Sweden). PBMCs (4 £ 105 cells per well) were
added in RPMI-1640 medium supplemented with 10% fetal calf
serum with negative control (medium alone) and the split virus
influenza H1N1 antigens from; A/New Caledonia/20/99,
A/Texas/36/91, A/Brisbane/59/07 and A/California/7/09 (X179a).
Plates were incubated overnight (37C, 5% CO2) and developed
the following day. The plates were read using an ImmunoscanTM
reader and associated software (CTL-Europe). The negative con-
trol was subtracted from the influenza-specific response.
Intracellular cytokine staining (ICS) for multi-functional
CD4C T cell responses
PBMCs from vaccinated subjects were stimulated overnight
with A/California/7/09 (X179a), A/New Caledonia/20/99 and
A/Brisbane/59/07 split virus antigens and the cells were stained
for intracellular Th1 cytokines IFN-g, IL-2 and TNF-a and the
percentage of single, or multiple cytokine producing CD4C T-
cells were analyzed by flow cytometry as described earlier.43
Statistical assays
Differences in the IFN-g, ASC and MBC ELISPOT
responses were analyzed by non-parametric Kruskal-Wallis test.
Correlations between pre-vaccination MBC responses against the
A(H1N1)pdm09 virus and seasonal influenza strains were deter-
mined by Spearman correlation coefficient analysis. The Kruskal-
Wallis and Spearman correlation analysis were performed by
GraphPad Prism version 6.00 for Mac (GraphPad software, La
Jolla, CA, USA). Differences between intracellular cytokine
responses at days 0 and 21 were determined by the student t test
and a partial permutation test by using SPICE version 5.1 soft-
ware, as described earlier.44 P < 0.05 was considered as signifi-
cant for all statistical tests.
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